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A comparative analysis of human 
and mouse islet G-protein coupled 
receptor expression
Stefan Amisten1, Patricio Atanes1, Ross Hawkes1, Inmaculada Ruz-Maldonado1, Bo Liu1, 
Fariborz Parandeh2, Min Zhao1, Guo Cai Huang1, Albert Salehi2 & Shanta J. Persaud1
G-protein coupled receptors (GPCRs) are essential for islet function, but most studies use rodent islets 
due to limited human islet availability. We have systematically compared the GPCR mRNA expression in 
human and mouse islets to determine to what extent mouse islets can be used as surrogates for human 
islets to study islet GPCR function, and we have identified species-specific expression of several GPCRs. 
The A3 receptor (ADORA3) was expressed only in mouse islets and the A3 agonist MRS 5698 inhibited 
glucose-induced insulin secretion from mouse islets, with no effect on human islets. Similarly, mRNAs 
encoding the galanin receptors GAL1 (GALR1), GAL2 (GALR2) and GAL3 GALR3) were abundantly 
expressed in mouse islets but present only at low levels in human islets, so that it reads (GALR3) and 
galanin inhibited insulin secretion only from mouse islets. Conversely, the sst1 receptor (SSTR1) was 
abundant only in human islets and its selective activation by CH 275 inhibited insulin secretion from 
human islets, with no effect on mouse islets. Our comprehensive human and mouse islet GPCR atlas has 
demonstrated that species differences do exist in islet GPCR expression and function, which are likely to 
impact on the translatability of mouse studies to the human context.
It is well-established that secretion of hormones from islets of Langerhans is regulated by activation of islet cell 
G-protein coupled receptors (GPCRs) by neurotransmitters, paracrine actions of islet hormones themselves, 
excluding insulin which acts through a tyrosine kinase receptor, and by circulating hormones1. Thus, it has been 
known for many years that parasympathetic and sympathetic neurotransmitters act at specific muscarinic and 
adrenergic GPCR subtypes to potentiate and inhibit the stimulatory effects of nutrients on insulin secretion, to 
allow fine-tuning of the insulin secretory response2. In addition, glucagon stimulates insulin and somatosta-
tin release, while somatostatin inhibits glucagon and insulin release3. Furthermore, GLP-1, an incretin released 
from the gastrointestinal tract following food intake, acts at GPCRs on islet β - and α -cells to stimulate insulin 
and inhibit glucagon secretion4, and GIP, another incretin, also potentiates glucose-induced insulin release. The 
GLP-1 receptor is probably the most well characterised of all islet GPCRs, and several GLP-1 receptor agonists 
and DPP4 inhibitor drugs that stabilise incretin levels are in widespread clinical use as therapies for type 2 dia-
betes (T2D)5. A number of other GPCRs, including GPR119, FFAR1, GPRC5B and GPRC5C, all of which are 
expressed by human islets1, have also emerged as drug target candidates for the treatment of T2D6,7.
In addition to the reasonably well-characterised GPCRs, some of which are outlined above, human islets 
express almost 300 additional GPCRs1,8,9, but most of these have poorly characterised roles in islet physiology1. 
Due to the limited availability of human islets, the vast majority of all physiological and pharmacological studies 
on the regulation of islet hormone secretion have been carried out using isolated rodent islets, particularly from a 
variety of mice strains. Although islets are readily available from both normal and transgenic mice, it is unclear to 
what extent data obtained by studying rodent islet function are translatable to the human context. In fact, mouse 
and human islets have distinct morphological arrangements, which may impact on their function10,11 and several 
studies comparing the gene expression profiles of human and rodent islets suggest that there are significant dif-
ferences, including in GPCR expression12–14. This has been confirmed functionally in experiments using isolated 
rodent and human islets where it has been reported that human islets express β -adrenergic receptors that are cou-
pled to elevation of insulin secretion, while β -adrenergic agonists have no effect on insulin release from rat islets15. 
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In addition, MT1 receptors, which are activated by the pineal hormone melatonin, are reported to be expressed 
by rodent β -cells but not by human β -cells16, and different classes of purinergic receptor regulate intracellular 
calcium levels in rodent17 and human18 β -cells.
To date there has not been a systematic review of the GPCR gene expression repertoires of rodent and human 
islets, so in the current study we have compared human islet GPCR mRNA profiles with those of islets isolated 
from outbred ICR mice and inbred C57BL/6 mice. We have used these data to identify a core set of GPCRs that 
are expressed in both human and mouse islets, as well as islet GPCRs that show species-restricted expression. The 
extensive GPCR gene expression profiles presented here will provide the scientific community with a comprehen-
sive comparative analysis of the mRNA expression of all functional human GPCRs and their mouse orthologues 
in human and mouse islets. This can then be used as a reference tool for the translation of mouse islet functional 
GPCR data to the human context, which will facilitate the evaluation of islet GPCRs as drug target candidates for 
novel diabetes therapies.
Results
Expression of GPCR mRNAs in islets isolated from C57 and ICR mice. The qPCR analyses indi-
cated that transcripts encoding 183 GPCRs of the 341 GPCR mRNAs analysed (53.7%) were expressed at levels 
greater than 0.001% of the mean mRNA expression of the reference genes Actb, Gapdh, Ppia, Tbp and Tfrc in 
islets isolated from ICR and C57 mice. The remaining 158 GPCR mRNAs were either absent or expressed only 
at exceedingly low levels (< 0.001% of the mean mRNA expression of the reference genes) in both mouse strains. 
It can be seen from Fig. 1 that the overall islet GPCR mRNA expression profiles in outbred ICR and inbred C57 
mouse strains were very similar. Thus, although there were 52 fewer GPCRs expressed by C57 mouse islets (227 
GPCR mRNAs vs 279 in C57 islets), there was a strong correlation between the expression patterns based on their 
levels relative to the reference genes (r2 = 0.95).
Strain-specific expression of GPCR mRNAs in mouse islets. 154 of the 183 GPCR mRNAs that were 
detected above trace levels were commonly expressed by both ICR and C57 islets, indicating that there are strik-
ing similarities in islet GPCR expression between the two mouse strains. In fact, ICR and C57 mouse islets shared 
eight out of ten of their most abundantly expressed GPCR mRNAs (Calcrl, Cckar, Ffar1, Galr1, Glp1r, Gpr158, 
Gpr56 and Gprc5c; Fig. 2a,b), suggesting that these GPCRs play important roles in the normal function of mouse 
islets. However, we did identify some strain-specific differences in GPCR mRNA expression such that 12 GPCR 
mRNAs were expressed only by C57 islets while 17 additional GPCR mRNAs were only detected in ICR islets 
(Supplementary Table 1).
Comparative analysis of GPCR mRNA expression by human and mouse islets. The relative 
expression of the ten most abundant GPCR mRNAs in human and mouse islets are presented in Fig. 2a–c. These 
figures indicate that while there was a high level of concordance between the mouse strains, as described above, 
Figure 1. Comparison of the relative expression of 341 GPCR mRNAs in islets isolated from the outbred 
ICR and inbred C57 mouse strains. Insert panel A has been enlarged to allow visualisation of GPCRs 
expressed above trace level only in ICR mouse islets. Data are presented as mean GPCR expression relative to 
the reference genes Actb, Gapdh, Ppia, Tbp and Tfrc from non-pooled biological replicates from four C57 and 
four ICR mice.
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only three of the ten most highly expressed human islet GPCR mRNAs were common to the ten most abundant 
mouse islet GPCR mRNAs. Nonetheless, in both mouse and human islets, the adhesion receptor GPR56 was the 
most abundantly expressed GPCR mRNA, with mRNA levels at ~20% and 50% of the mean mRNA expression 
of the five reference genes in human islets and mouse islets respectively. The GLP-1 receptor, which is the target 
for incretin mimetic therapies for type 2 diabetes that are known to stimulate insulin secretion in rodents and 
humans19, was another abundant GPCR in human and mouse islets. The third highly expressed GPCR mRNA 
common to human and mouse islets was FFAR1, which is activated by long chain fatty acids. The receptors iden-
tified in Fig. 2a–c were all expressed at > 5% of the mean mRNA expression levels of the five reference genes and 
represented the most abundant GPCRs. However, overall the mean mRNA expression of all quantifiable islet 
GPCRs, relative to the reference genes, was 0.53% in human islets (206 GPCRs) and 1.4% in mouse islets (1.34% 
in ICR mouse islets; 167 GPCRs and 1.37% in C57 islets; 163 GPCRs). Thus, although there are a large number 
of GPCR mRNAs expressed by mouse and human islets, the majority of them are of low abundance. Expression 
of all human GPCR mRNAs and their mouse orthologues relative to ACTB, GAPDH, PPIA, TBP and TFRC are 
presented in Supplementary Figure 1.
The similarities and differences in islet GPCR mRNA expression between human islets and the two mouse 
strains are illustrated in Fig. 2d,e. The analysis was carried out with all detected GPCRs, including GPCRs present 
only at trace level (Fig. 2d) and also with only those GPCRs with mRNA expression above trace level (Fig. 2e), as 
these are more likely to affect islet function. A core set of 189 GPCR mRNAs (53.7% of all human GPCRs) were 
expressed in both human and ICR/C57 mouse islets (Fig. 2d). 9.9% of all GPCR mRNAs (35 GPCRs) were found 
exclusively in human islets, and 63 receptors (18.5% of all investigated GPCRs) were expressed exclusively in 
mouse islets and not in human islets (Fig. 2d). When only GPCR mRNAs present above trace level were exam-
ined, a core set of 121 GPCR mRNAs (34.4% of all GPCRs) was expressed in both human and ICR/C57 mouse 
Figure 2. Summary of the relative expression of the ten most abundant GPCR mRNAs in outbred ICR 
mouse islets (a), inbred C57 mouse islets (b) and human islets (c). Colour coding in mouse islets according 
to similarities with human islet GPCR expression. White fields represent mouse islet GPCR mRNAs that are 
not among the ten most abundant GPCR mRNAs in human islets. Data for each GPCR are presented as mean 
% of the mRNA expression of all GPCRs in each islet type. (d,e) Species/strain distribution of all islet GPCR 
mRNAs in C57 and ICR mouse islets and human islets with all GPCR mRNAs (d) and only with GPCR mRNAs 
expressed above trace level (e).
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islets. 20.7% of all GPCRs (71 receptors) were expressed above trace level only in human islets, whereas 48 recep-
tors (14.1%) were expressed above trace level only in mouse islets (Fig. 2e).
There was a reasonable similarity in the GPCR mRNA expression profiles of human and mouse islets (ICR, r2: 
0.36; C57, r2: 0.31), but the inter-species differences were much greater than the small inter-strain differences, as 
expected. Our data indicate that ~36% of all GPCRs screened were expressed above trace levels in both human 
and mouse islets, and a core set of 121 GPCR mRNAs were expressed by islets of both species (Fig. 3a,b). The 
enrichment of mRNAs encoding these 121 GPCRs in human and mouse islets was determined relative to mRNA 
expression levels of the five reference genes to allow direct comparison of GPCR expression patterns between 
species (Fig. 4a,b). This indicated that although a large number of GPCR mRNAs are expressed by both human 
and mouse islets, there are significant species differences in their abundance. Compared to human islets, mRNAs 
encoding 68 GPCRs were at least 3 fold enriched in mouse islets, and 17 of these GPCRs (Adra2a, CalCrl, Cckar, 
Chrm3, Fzd3, Galr1, Gipr, Glp1r, Gpr116, Gpr125, Gpr158, Gpr56, Gprc5c, Lgr4, Oxtr, Ptger3, Vipr1) were also 
among the 25 most abundant mouse islet GPCR mRNAs (Fig. 3a,b). Four GPCR mRNAs (GPR44, GPR126, 
C5AR1, GPR135) were > 3 fold enriched in human islets compared to mouse islets (Fig. 3a,b). Overall, 72 of the 
121 islet GPCR mRNAs expressed by both human and mouse islets differed < 3 fold in mRNA expression.
Approximately 10% of all GPCR mRNAs (ICR: 38 GPCRs; C57: 35 GPCRs; 43 GPCRs in total) were expressed 
exclusively in mouse islets, with either trace or no expression at all in human islets. In particular, mRNAs encod-
ing the GAL1 (GALR1), GAL2 (GALR2) and GAL3 (GALR3), CELSR1, adenosine A3 (ADORA3), LPA6 (LPAR6) 
and GPR85 receptors were abundantly expressed in mouse islets but were either absent or expressed at very 
low level in human islets (Supplementary Figure 1). Similarly, we found that 81 GPCR mRNAs were preferen-
tially expressed in human islets and were absent or expressed only at trace level in islets isolated from one or 
both of the mouse strains. The most abundant of the human islet-specific GPCR mRNAs were those encoding 
the 5-HT1F (HTR1F), secretin (SCTR), α 2C adrenergic (ADRA2C), sst1 (SSTR1) and mGlu4 (GRM4) receptors 
(Supplementary Figure 1). In addition, three human-specific GPCR genes (GPR148, OXER1 and P2RY8), which 
do not exist in the mouse genome, were also expressed above trace levels in human islets (Fig. 5).
Functional validation of human or mouse islet-specific GPCR expression. Selective expression 
of A3 receptors by mouse islets was confirmed by experiments using the A3 receptor agonist MRS 5698, which 
caused significant inhibition of glucose-induced insulin secretion from mouse, but not human islets. Appropriate 
Gi-coupling in human islets was confirmed by the use of the α 2-adrenergic-selective agonist clonidine, which 
inhibited insulin secretion, as expected (Fig. 6b,c). Similarly, activation of the highly expressed galanin recep-
tors on mouse islets by exposure to mouse galanin-(2–29) resulted in concentration-dependent inhibition of 
insulin secretion, whereas human galanin-(1–30) did not significantly affect insulin secretion from human islets 
(Fig. 7a,b). The Gi-coupled sst1 (SSTR1) receptor mRNA was abundantly expressed in human islets, but only 
present at very low levels in mouse islets. Functional evaluation of the sst1 receptor agonist CH 275 indicated that 
it significantly inhibited insulin secretion from human islets, but it had no effect on insulin release from mouse 
islets (Fig. 8a,b).
Discussion
A recent review analysing drugs acting on human therapeutic targets indicated that GPCRs are the largest class of 
targets for the development of new pharmaceutical products20. However, despite the use of GPCR-targeted drugs 
to treat a variety of clinical conditions such as asthma and hypertension only the GLP-1 receptor has been used 
successfully in treating T2D. This limited application of GPCR-based therapies for T2D is due, in part, to the poor 
functional characterisation of the majority of islet-expressed GPCRs and this is further exacerbated by the insuf-
ficient availability of human islets for identifying functional effects of GPCRs that are known to be expressed by 
islets. Rodent islets, in particular those isolated from mice, are therefore often relied upon as translational models. 
Structural differences between rodent and human islets are well documented10,11, which poses a question of the 
suitability of using rodent islets, in particular mouse islets, as translation models for predicting GPCR-mediated 
regulation of human islet function. Therefore, in this study, we have objectively evaluated the extent of the sim-
ilarity of GPCR expression between the primary therapeutic target tissue, human islets, and the primary model 
system tissue, mouse islets.
Quantification of gene expression is the method of choice for systematic comparison of GPCR expression by 
isolated human and mouse islets, and qPCR is a highly sensitive, cost-effective and versatile method for detecting 
low abundance GPCRs21. Microarray has also traditionally been used for the quantification of gene expression, 
but this technology is less suitable for the detection of low abundance transcripts, which represent the majority of 
all GPCR mRNAs22. More recently, RNA-sequencing has emerged as a suitable alternative to qPCR. However this 
approach is still relatively costly, requires complex computational biology to fully analyse cellular transcriptome 
data and it requires post-analysis validation of gene expression data by a different platform, such as qPCR, which 
more closely mirrors gene expression data obtained by RNA-sequencing than by microarray22–24. Thus, the use of 
qPCR with validated primers for mRNAs encoding GPCRs, as used here, provides a focused strategy for defining 
and comparing the GPCRomes of mouse and human islets.
As expected, there was a very close correlation between GPCR mRNA profiles of islets isolated from the 
outbred ICR strain and inbred C57 strain of mice. Nonetheless, differences were observed, which may have an 
impact on the choice of model for functional characterisations. For example, C57 mouse islets did not express 
the sst3 receptor (Sstr3) so islets from this strain would not be suitable for characterising somatostatin signalling 
through this receptor subtype. Conversely, the orphan GPCR Gpr45 is expressed at moderately high levels in 
C57 islets but only at very low levels in ICR islets. This suggests that islets from C57 mice would be the model 
of choice for identifying the role of this receptor once appropriate tools are available, although relevance to the 
human situation is very low since GPR45 mRNA is only expressed at trace levels by human islets. In addition, 
www.nature.com/scientificreports/
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Figure 3. (a,b) Mean relative mRNA expression of human GPCRs in human islets and mouse GPCR 
orthologues in islets from ICR (a) and C57 (b) mice. Data are presented as mean GPCR mRNA 
expression ± SEM relative to the reference genes ACTB, GAPDH, PPIA, TBP and TFRC. Data generated using 
non-pooled islet RNA from four ICR and four C57 mice and four non-pooled human islet preparations. Insert 
panels A and B represent enlarged areas of the scatter plots, added to allow visualisation of individual GPCR 
mRNAs. *: excluding bitter taste receptors (TAS2Rs).
www.nature.com/scientificreports/
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although eight out of the ten most highly expressed GPCR mRNAs were common to C57 and ICR islets, Fzd3 
and Gabbr2 were higher in ICR islets while Galr3 and Gipr were higher in C57 islets. Despite this, there was still 
a high similarity of expression levels of Fzd3, Gabbr2, Galr3 and Gipr between ICR and C57 islets, as shown in 
Supplementary Figure 1.
There have been earlier comparisons of gene expression in mouse and human islets12–14, but no focused study 
aimed at identifying similarities and differences in GPCR mRNA expression in human and mouse islets has been 
reported. Understanding which GPCRs are present on human islets, and if mouse islets can be used as a trans-
lational model system, are essential for evaluating whether particular islet GPCRs are potential novel targets for 
the development of new diabetes therapeutics. Interestingly, we have shown that GLP-1 receptors are in the top 
10 GPCRs expressed by both mouse and human islets, so discoveries of the beneficial effects of GLP-1 agonists 
on glucose homeostasis in mice are directly translatable to the human situation, as is seen with the successful use 
Figure 4. (a,b) Species enrichment of the 121 islet GPCR mRNAs expressed above trace level in both human 
and mouse islets. Mean ICR and C57 GPCR mRNA expression levels were compared to the mRNA expression 
of human islet GPCRs. mRNAs encoding 68 GPCRs were > 3 fold enriched in mouse islets (a), 17 of these 
GPCRs (Adra2a, CalCrl, Cckar, Chrm3, Fzd3, Galr1, Gipr, Glp1r, Gpr116, Gpr125, Gpr158, Gpr56, Gprc5c, 
Lgr4, Oxtr, Ptger3, Vipr1) are also among the 25 most abundant mouse islet GPCR mRNAs (highlighted with * 
in figure a). Four GPCR mRNAs were > 3 fold enriched in human islets (b). Data are presented as a ratio of the 
mean GPCR expression relative to the reference genes ACTB, GAPDH, PPIA, TBP and TFRC in human and 
mouse islets (i.e. mean of GPCR expression in ICR and C57 islets), and was generated using non-pooled islet 
RNA from four ICR and four C57 mice and four non-pooled human islet preparations.
www.nature.com/scientificreports/
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of stable GLP-1 analogues as T2D therapies. We also found that FFAR1, which codes for a GPCR that is activated 
by long chain fatty acids, is highly expressed in human and mouse islets. FFAR1 agonists have been considered 
as novel therapies for T2D, but the development of a promising candidate, TAK-87525, has been discontinued 
because of adverse effects on the liver26.
We have also identified that several well-characterised GPCRs (CASR, GPRC5B, GPR119, F2RL1), which are 
either current drug targets or under evaluation as potential diabetes therapeutic targets, are highly expressed in 
both human and mouse islets. In addition, other highly expressed human islet GPCRs (e.g. ADGRG1 [GPR56], 
LPHN1, ELTD1) provide scope for further analysis, and the observation that ADGRG1 is also highly expressed 
in mouse islets indicates that these can be used with confidence to identify signalling downstream of this receptor. 
An important role for ADGRG1 in β -cell function and survival has recently been reported27, whereas the role of 
ELTD1 and LPHN1 in islet function remain unknown.
Our qPCR analyses have also indicated that a large number of GPCR mRNAs were expressed at very low levels 
(< 0.001% of the mean mRNA expression of the five reference genes ACTB, GAPDH, PPIA, TBP and TFRC) in 
both human and mouse islets. At such low levels, it is not possible to accurately quantify the mRNA expression, 
as it falls outside of the linear range of detection for the QuantiTect qPCR primer assays. These mRNAs are 
Figure 5. Relative expression in human islets of GPCRs that are absent in the mouse genome. Data are 
presented as mean ± SEM GPCR expression relative to the reference genes ACTB, GAPDH, PPIA, TBP and 
TFRC. n = four human islet donors. T denotes trace expression.
Figure 6. Confirmation of mouse islet-specific expression and function of the A3 (Adora3) receptor. The A3 
receptor agonist MRS 5698 had no effect on insulin secretion from human islets (a), but significantly inhibited 
glucose-stimulated insulin secretion from mouse islets (b). The Gi-coupled control agonist clonidine had 
significant inhibitory effects in both mouse and human islets. *p < 0.05; ***p < 0.001 versus secretion at 20 mM 
glucose.
www.nature.com/scientificreports/
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nevertheless present in human and mouse islets, albeit at low copy numbers, and they are likely to be translated 
into GPCR proteins. It is difficult to evaluate the physiological impact of these low abundance receptor pro-
teins on islet function. In fact, mRNAs encoding receptors present at trace levels are expressed at approximately 
16,000–45,000 fold lower concentrations than the mRNA encoding the most abundant islet GPCR, ADGRG1 
[GPR56]. We cannot exclude that GPCR mRNAs present at trace level may be transcribed into proteins capable 
of influencing islet function, but based on the assumption that the mRNAs encoding these receptors are expressed 
at very low levels, and therefore likely to result in low levels of GPCR protein, we hypothesise that GPCRs with 
mRNA expression at trace level in islets are less likely to have a major impact on islet function compared to 
GPCRs with more abundant mRNA expression. This is exemplified by our functional studies on the inhibitory 
effects of the A3 and galanin receptors on insulin secretion: mRNAs encoding the A3, GAL1 and GAL3 receptor 
mRNAs are highly expressed in mouse islets, but absent or only present at trace levels in human islets, and this 
Figure 7. The effect on insulin secretion by the galanin receptor agonist galanin in human (a) and mouse (b) 
islets. Human galanin-(1–30) had no effect on insulin secretion from human islets, whereas insulin secretion 
from mouse islets was significantly inhibited by mouse galanin-(2–29) (b). n = 8 islets in each treatment group. 
*p < 0.05; **p < 0.01; ***p < 0.001.
Figure 8. The effect of the Sst1 receptor agonist CH 275 on the secretion of insulin from human (a) and mouse 
(b) islets at 2 and 20 mM glucose. A dose-dependent inhibition of insulin secretion by CH 275 was observed 
in human islets (a), whereas CH275 had no effect on insulin secretion from mouse islets (b). *p < 0.05; 
***p < 0.001.
www.nature.com/scientificreports/
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in turn translated into a clear inhibitory effect on insulin secretion following activation of the GAL1/GAL3 or A3 
receptors by exogenous agonists in mouse islets, while there was no significant effect on insulin secretion from 
human islets. Similar species-specific functional effects were observed for activation of the sst1 receptor, which is 
abundantly expressed in human islets but only present at very low levels in mouse islets. Consequently, in human 
islets, activation of the Gi-coupled sst1 receptor by the selective sst1 receptor agonist CH 275 led to inhibition of 
insulin secretion, whereas no effects on mouse islet insulin secretion were observed.
The importance of determining the expression by human islets of GPCRs that have been investigated in rodent 
studies is illustrated by earlier studies where there is a mismatch between GPCR expression by mouse and human 
islets. For example, it has been reported that mRNA expression of the trace amine receptor Taar1 is restricted to 
islets in mice8, suggesting that this receptor might be a potential target for novel diabetes therapeutics. However, 
subsequent studies by ourselves and others using both qPCR and RNA-sequencing have shown that TAAR1 is 
expressed at very low levels in human islets1,28, thus making it a much less likely target for islet GPCR-focused 
therapeutics. Similarly, the abundant expression of several other mouse islet GPCRs - A3 (Adora3), Celsr1, GAL1 
(Galr1), GAL2 (Galr2), GAL3 (Galr3), Gpr158, Lpar6, S1pr3 and OT (Oxtr) - can also be ruled out as potential 
human islet GPCR drug targets based on their low (or absent) expression in human islets.
In summary, in this study, we have systematically compared the expression of all known human GPCR 
mRNAs and their mouse orthologues in human and mouse islets and mapped the similarities and differences in 
islet GPCR mRNA expression between the two species. We have demonstrated that there is a common expression 
of a number of islet GPCRs between mouse and man, which allows mouse islets to be used as appropriate surro-
gates for human islets when investigating the function of these GPCRs in islets. However, we have also identified 
that significant differences do exist in GPCR expression between mouse and human islets, so care should be taken 
in the choice of model for functional analyses to ensure that data obtained using mouse islets are relevant to the 
human situation. Overall, the data presented here provide an essential resource for the translation of mouse islet 
functional data to the human islet context, which will facilitate the identification of islet GPCRs for evaluation as 
potential novel drug targets for diabetes.
Research Design and Methods
Islet isolation and culture. Islets were isolated from 10–12 week old male mice of the inbred C57BL/6 
(C57; Charles River) and outbred ICR (Harlan) strains by collagenase digestion of the exocrine pancreas29. All 
animal procedures were approved by the King’s College London Ethics Committee and carried out in accordance 
with the UK Home Office Animals (Scientific Procedures) Act 1986.
Human islets were isolated from non-diabetic organ donors at the King’s College London Human Islet 
Isolation Unit30 with appropriate ethical approval and donor consent for research (Protocol number 01–082, 
Human Islet Isolation and Research). An assent form was completed by a relative of the pancreas donor for all 
islets used for research, and all experiments carried out on human islets were performed in accordance with the 
relevant guidelines and regulations as set out by the King’s College London Ethics Committee.
Isolated mouse and human islets were maintained in culture overnight (mouse: RPMI 1640; human: CMRL) 
at 37 °C, 5% CO2 before extraction of RNA.
RNA extraction and quantitative real-time PCR. Olfactory, pseudogene and vomeronasal GPCRs were 
not included in the study and the bitter taste receptors (TAS2Rs) were also excluded as the nomenclature identify-
ing the exact mouse TAS2R orthologues is very unclear, often with identical gene symbols being used for several 
different mouse bitter taste receptor genes. Total non-pooled RNA from ~200 islets isolated from four C57 and 
four ICR mice and from four non-diabetic human islet donors (2 male and 2 female, donor age 49.5 ± 3.5 years 
old, BMI 28.2 ± 2.3 kg/m2) was isolated using a modified TRIzol protocol followed by RNA clean-up on RNEasy 
MinElute columns (Qiagen)31. 500 ng of islet total RNA from each mouse or human donor was converted into 
cDNA using the TaqMan RT-PCR kit (Life Technologies) as described elsewhere21,32. Quantitative real-time PCR 
(qPCR) with Qiagen QuantiTect SYBR Green mouse or human primer assays was performed using islet cDNAs 
to quantify the expression of 352 non-olfactory, non-vomeronasal, non-bitter taste human GPCRs and 341 mouse 
orthologues as described in detail elsewhere21,31,32. For both mouse and human islets, GPCR mRNA levels were 
expressed relative to the reference genes ACTB, GAPDH, PPIA, TBP and TFRC. All GPCR and reference gene 
primer efficiency (E)32 values were in the range of 1.85–2.15. For all GPCR and reference gene quantifications, 
template cDNAs were diluted in such a way that all quantified genes returned Ct values < 30. Genes expressed 
< 0.001% of the mean mRNA level of the five reference genes were considered to be present only at trace level, as 
their expression was less than the lower limit of linear quantification of the QuantiTect primer assays. The human 
and mouse qPCR primers used for amplifications are listed in Supplementary Table 2. Enrichment of GPCR 
mRNA expression in human islets were calculated using the formula below:
Enrichment of GPCR expression = Human islet GPCR expression relative to reference genes/Mean mouse islet 
GPCR expression relative to reference genes in ICR and C57 mouse islets.
For enrichment of GPCR expression in mouse islets, the inverse of the above formula was used.
Insulin secretion. Human and mouse isolated islets were cultured overnight in either CMRL or RPMI 
with 11 mM glucose supplemented with 10% fetal bovine serum. After a 1-h pre-incubation in physiological 
salt solution33 containing 2 mM glucose, insulin release was assessed by static incubation. Briefly, groups of five 
size-matched islets were hand-picked into 1.5 ml microcentrifuge tubes and incubated for 1 hour in a physio-
logical salt solution at 37 °C in the absence or presence of the A3 receptor-selective agonist MRS 5698, human 
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galanin-(1–30), mouse galanin-(2–29) or the sst1 agonist CH 275 (Tocris Bioscience). Insulin secreted into the 
supernatant was quantified by radioimmunoassay as described elsewhere34.
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